This week, the ratings of five pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Alcobra Ltd.’s (ADHD) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. In Portfolio Grader’s specific subcategories of Earnings Momentum, Equity and Cash Flow, ADHD also gets an F. For more information, get Portfolio Grader’s complete analysis of ADHD stock.
Lipocine, Inc. (LPCN) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The stock gets F’s in Earnings Revisions, Equity and Cash Flow. Trade volume is up 1475.8% from the previous week. To get an in-depth look at LPCN, get Portfolio Grader’s complete analysis of LPCN stock.
Perrigo Co. Plc (PRGO) gets weaker ratings this week as last week’s C drops to a D. The Perrigo manufactures, distributes and markets pharmaceutical and nutritional products. The stock also rates an F in Margin Growth. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. The trailing PE Ratio for the stock is 115.50. For more information, get Portfolio Grader’s complete analysis of PRGO stock.
This is a rough week for Aratana Therapeutics, Inc. (PETX). The company’s rating falls to D from the previous week’s C. The stock gets F’s in Earnings Momentum and Equity. The stock has a trailing PE Ratio of 157.20. To get an in-depth look at PETX, get Portfolio Grader’s complete analysis of PETX stock.
The rating of AcelRx Pharmaceuticals, Inc. (ACRX) slips from a C to a D. AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The stock also gets an F in Earnings Momentum. As of Feb. 5, 2015, 20.4% of outstanding AcelRx Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of ACRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
